Several analysts have recently updated their ratings and price targets for DBV Technologies (NASDAQ: DBVT):

  • 10/24/2017 – DBV Technologies was downgraded by analysts at Societe Generale from a “buy” rating to a “sell” rating.
  • 10/24/2017 – DBV Technologies was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $32.00 price target on the stock. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
  • 10/23/2017 – DBV Technologies was given a new $49.00 price target on by analysts at Leerink Swann. They now have an “outperform” rating on the stock.
  • 10/23/2017 – DBV Technologies was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating.
  • 10/23/2017 – DBV Technologies had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
  • 10/23/2017 – DBV Technologies had its price target lowered by analysts at Barclays PLC from $58.00 to $30.00. They now have an “overweight” rating on the stock.
  • 10/8/2017 – DBV Technologies had its price target raised by analysts at Deutsche Bank AG from $46.00 to $56.00.
  • 10/6/2017 – DBV Technologies had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $72.00 price target on the stock, up previously from $70.00.
  • 10/2/2017 – DBV Technologies had its price target raised by analysts at Citigroup Inc. from $43.00 to $57.00. They now have a “buy” rating on the stock.
  • 9/29/2017 – DBV Technologies was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
  • 9/26/2017 – DBV Technologies was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 9/18/2017 – DBV Technologies was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $48.00 price target on the stock. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
  • 9/14/2017 – DBV Technologies was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
  • 9/12/2017 – DBV Technologies had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $51.00 price target on the stock.
  • 9/12/2017 – DBV Technologies was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $49.00 price target on the stock. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
  • 9/8/2017 – DBV Technologies was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
  • 8/31/2017 – DBV Technologies had its “buy” rating reaffirmed by analysts at Jefferies Group LLC.
  • 8/31/2017 – DBV Technologies was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
  • 8/29/2017 – DBV Technologies was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $50.00 price target on the stock. According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “

Shares of DBV Technologies S.A. (NASDAQ DBVT) opened at 27.02 on Wednesday. The company’s 50-day moving average is $43.99 and its 200 day moving average is $39.46. The stock’s market capitalization is $1.24 billion. DBV Technologies S.A. has a 52 week low of $22.33 and a 52 week high of $50.57.

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Receive News & Ratings for DBV Technologies SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA and related companies with MarketBeat.com's FREE daily email newsletter.